AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05391568 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle.
Study NCT05768425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time quaking-induced conversion (RT-QuIC)
Description: RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
Study NCT05768425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive test
Description: Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
Study NCT04416113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photobiomodulation and photodynamic therapy
Description: antiviral treatment
Study NCT05927987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: Problem Management Plus (PM+) is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011; Tol et al., 2013). The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem-solving, stress management, behavioural activation, and accessing social support. PM+ has three core features. It is brief (five sessions given in five weeks), delivered by paraprofessionals (PM+ helpers) and transdiagnostic. The PM+ helpers will be supervised by mental health care specialists.
Study NCT06521216 — intervention group
Intervention type: DRUG
Intervention: Ferrous sulfate
Description: all patients will receive 200 mg elemental iron (ferrous sulphate)
Study NCT06202469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement 1
Description: Creatine monohydrate (5 g/day)
Study NCT06202469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement 2
Description: Creatine monohydrate (5 g/day) plus ubiquinol (200 mg/day)
Study NCT06202469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (inulin)
Study NCT05235165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood
Study NCT05235165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05235165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05768425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Motor examination
Description: Unified Parkinsons Rating Scale (UPDRS)
Study NCT05872295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKS014
Description: IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
Study NCT05019755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002(IN-115314) capsule
Description: Oral Administration of IN-A002(IN-115314), single dose
Study NCT05507060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating MESH nebulizer (Aerogen Ultra)
Description: Medication will be applied with Vibrating MESH nebulizer
Study NCT05507060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet nebulizers (Philips Respironics)
Description: Medication will be applied with Jet nebulizers
Study NCT06256029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
Study NCT05424887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study NCT04997616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)
Description: Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
Study NCT05402813 — intervention group
Intervention type: OTHER
Intervention: Pure Tone Audiometry Assessment
Description: Collection of Pure Tone Audiometry data performed in routine practice during study period
Study NCT05402813 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: Collection of Quality of Life questionnaire's answers during study period
Study NCT05872724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
Description: * Radiation therapy:~  1. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy.
Study NCT05872724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (small pelvic) + Zimberelimab
Description: Radiation therapy:~1. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy.
Study NCT04650113 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTA material
Description: Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
Study NCT04650113 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MTA material
Description: Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
Study NCT05748119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
Study NCT05235165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopy
Description: Undergo video-assisted thoracoscopic surgery or VATS
Study NCT05235165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Undergo open thoracic surgery
Study NCT06163287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Dietary supplement containing molecular hydrogen
Study NCT05685433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin Tibial Nerve Stimulation
Description: Subcutaneous stimulation of the tibial nerve using the eCoin device.
Study NCT05748119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MEB-1170
Description: Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
Study NCT06163287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert substance
Study NCT05748119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent number and size of capsules containing placebo
Study NCT06545565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium acetate group will receive sodium acetate in the neonatal PN.
Description: This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
Study NCT06545565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride group will receive sodium chloride in the neonatal PN.
Description: This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
Study NCT06206850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Evaluation
Description: A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation
Description: A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Passive Ankle Stiffness
Description: Participants will be seated in a dynamometer with their trunk and thigh stabilized to the dynamometer chair, ankle joint aligned with the rotational axis of the dynamometer, and foot stabilized to the foot plate. EMG activity will be recorded from lower limb muscles (gastrocnemius, soleus, tibialis anterior) during all isolated contractions. Participants will first perform three maximum voluntary isometric contractions (MVIC) while seated in a dynamometer. Participants will then perform three isokinetic dorsiflexion tasks while using electromyographic biofeedback at a prescribed level of 50% MVIC soleus activation. The slope of the linear best fit line from the ankle moment vs. angle plot will yield total ankle joint stiffness (i.e., active + passive) at a fixed activation. In three additional trials, the dynamometer will move the ankle joint through the same motion without active subject resistance and the same analytical procedures will derive passive ankle joint stiffness.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Passive Ankle Stiffness
Description: Participants will be seated in a dynamometer with their trunk and thigh stabilized to the dynamometer chair, ankle joint aligned with the rotational axis of the dynamometer, and foot stabilized to the foot plate. EMG activity will be recorded from lower limb muscles (gastrocnemius, soleus, tibialis anterior) during all isolated contractions. Participants will first perform three maximum voluntary isometric contractions (MVIC) while seated in a dynamometer. Participants will then perform three isokinetic dorsiflexion tasks while using electromyographic biofeedback at a prescribed level of 50% MVIC soleus activation. The slope of the linear best fit line from the ankle moment vs. angle plot will yield total ankle joint stiffness (i.e., active + passive) at a fixed activation. In three additional trials, the dynamometer will move the ankle joint through the same motion without active subject resistance and the same analytical procedures will derive passive ankle joint stiffness.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Biomechanics
Description: Three-dimensional gait analysis is performed as participants walk at a self-selected speed on an instrumented treadmill. Reflective markers are attached to lower extremity segments. Elastic bands are wrapped around the thighs, calves, and pelvis to which small, thermoplastic shells containing reflective markers are attached. Additional markers are taped to the participant's shoes and on the upper back, shoulder, hip, knee, and ankle joints with adhesive skin tape. Marker data is collected using a 7-camera motion analysis system (Vicon Inc., USA). Vicon motion analysis cameras will collect the location of the retroreflective markers in Vicon Nexus software.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Biomechanics
Description: Three-dimensional gait analysis is performed as participants walk at a self-selected speed on an instrumented treadmill. Reflective markers are attached to lower extremity segments. Elastic bands are wrapped around the thighs, calves, and pelvis to which small, thermoplastic shells containing reflective markers are attached. Additional markers are taped to the participant's shoes and on the upper back, shoulder, hip, knee, and ankle joints with adhesive skin tape. Marker data is collected using a 7-camera motion analysis system (Vicon Inc., USA). Vicon motion analysis cameras will collect the location of the retroreflective markers in Vicon Nexus software.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Biofeedback
Description: Audio-visual biofeedback will be provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map will represent the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target will be provided using the heat map colors of red and target line on the bar graph. For propulsion biofeedback, a visual display with a marker will represent the current propulsion (peak AGRF) and a target provided to modulate propulsion. The plantar pressure and AGRF measurements from the participant's baseline walking trials will be used to determine customized biofeedback targets.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Biofeedback
Description: Audio-visual biofeedback will be provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map will represent the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target will be provided using the heat map colors of red and target line on the bar graph. For propulsion biofeedback, a visual display with a marker will represent the current propulsion (peak AGRF) and a target provided to modulate propulsion. The plantar pressure and AGRF measurements from the participant's baseline walking trials will be used to determine customized biofeedback targets.
Study NCT06116708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalogon AF Prototype Smart Cushion
Description: The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
Study NCT06116708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Seat Cushion from Air Force
Description: This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
Study NCT06516315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound examination.
Description: Preoperative ultrasound examination performed the day before or the day of surgery.
Study NCT06516315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroperatoire angiography procedure and QFR analysis
Description: Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
Study NCT04676334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily.
Study NCT06169384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic adenoidectomy
Description: Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
Study NCT04174846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use therapeutic food (RUTF)
Description: SAM children will receive approximately 190 kcal/kg/day of standard RUTF
Study NCT04174846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use-supplementary food (RUSF)
Description: SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
Study NCT06006741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM-specific universal CAR T cells
Description: Infusion of MM-specific universal CAR T cells
Study NCT06271122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary activation assessed by magnetic stimulation
Description: Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau.
Study NCT06032468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC Intellicare
Description: wearable devices to guide rehabilitation exercise
Study NCT05424887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study NCT06032468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation sheets
Description: rehabilitation exercise sheets to guide rehabilitation exercise
Study NCT04996017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
Study NCT04996017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
Study NCT04722601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
Study NCT04994600 — intervention group
Intervention type: OTHER
Intervention: Reduces number of question items
Description: The number of alarm fatigue questions are reduced to about 15 in the CFA_2nd_phase group.
Study NCT04907903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).